A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis

Inclusion Criteria

• •must be at least 18 years when fisrt dose of Trilaciclib, regardless of gender；
• •ECOG-PS score of 0-1，and no worsening in the 2 weeks before the study drug；
• •expected survival≥12 weeks；
• •Advanced non-small cell lung cancer with leptomeningeal metastasis；
• •with an Ommaya sac has been implanted；
• •At least one measurable lesion meeting RECIST1.1 criteria was present；
• •Laboratory tests met the following criteria: hemoglobin ≥100 g/L (female), 110g/L (male) ；neutrophil count ≥ 2×109/L ；platelet count ≥100×109/L; Creatinine ≤ 15mg/L or creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula); Total bilirubin ≤ 1.5× upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or 5× ULN (for patients with liver metastases); Albumin ≥ 30 g/L;
• •Patients of reproductive age(including female and male patients'female companions)must use effective birth control measures;
• •Voluntarily participate and sign informed consent;